Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.

Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A, Barnes J, Ecklund D, Klingner E, Koepp M, Long JD, Natarajan S, Thornell B, Yankey J, Bermel RA, Debbins JP, Huang X, Jagodnik P, Lowe MJ, Nakamura K, Narayanan S, Sakaie KE, Thoomukuntla B, Zhou X, Krieger S, Alvarez E, Apperson M, Bashir K, Cohen BA, Coyle PK, Delgado S, Dewitt LD, Flores A, Giesser BS, Goldman MD, Jubelt B, Lava N, Lynch SG, Moses H, Ontaneda D, Perumal JS, Racke M, Repovic P, Riley CS, Severson C, Shinnar S, Suski V, Weinstock-Guttman B, Yadav V, Zabeti A; NN102/SPRINT-MS Trial Investigators.

N Engl J Med. 2018 Aug 30;379(9):846-855. doi: 10.1056/NEJMoa1803583.

2.

Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.

Fox RJ, Coffey CS, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Conwit R, Naismith R, Ashokkumar A, Bermel R, Ecklund D, Koepp M, Long J, Natarajan S, Ramachandran S, Skaramagas T, Thornell B, Yankey J, Agius M, Bashir K, Cohen B, Coyle P, Delgado S, Dewitt D, Flores A, Giesser B, Goldman M, Jubelt B, Lava N, Lynch S, Miravalle A, Moses H, Ontaneda D, Perumal J, Racke M, Repovic P, Riley C, Severson C, Shinnar S, Suski V, Weinstock-Gutman B, Yadav V, Zabeti A.

Contemp Clin Trials. 2016 Sep;50:166-77. doi: 10.1016/j.cct.2016.08.009. Epub 2016 Aug 10.

3.

Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC).

Zivadinov R, Cookfair DL, Krupp L, Miller AE, Lava N, Coyle PK, Goodman AD, Jubelt B, Lenihan M, Herbert J, Gottesman M, Snyder DH, Apatoff BR, Teter BE, Perel AB, Munschauer F, Weinstock-Guttman B.

BMC Neurol. 2016 Jul 15;16:102. doi: 10.1186/s12883-016-0623-2.

4.

Enterovirus/picornavirus infections.

Jubelt B, Lipton HL.

Handb Clin Neurol. 2014;123:379-416. doi: 10.1016/B978-0-444-53488-0.00018-3. Review. No abstract available.

PMID:
25015496
5.

Infectious myelitis.

Mihai C, Jubelt B.

Curr Neurol Neurosci Rep. 2012 Dec;12(6):633-41. doi: 10.1007/s11910-012-0306-3. Review.

PMID:
22927022
6.

Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patients.

Christophi GP, Gruber RC, Panos M, Christophi RL, Jubelt B, Massa PT.

Clin Immunol. 2012 Mar;142(3):308-19. doi: 10.1016/j.clim.2011.11.007. Epub 2011 Dec 2.

7.

Rhombencephalitis / brainstem encephalitis.

Jubelt B, Mihai C, Li TM, Veerapaneni P.

Curr Neurol Neurosci Rep. 2011 Dec;11(6):543-52. doi: 10.1007/s11910-011-0228-5. Review.

PMID:
21956758
8.

A West Nile virus vaccine.

Afzal U, Jubelt B.

Curr Neurol Neurosci Rep. 2011 Dec;11(6):517-9. doi: 10.1007/s11910-011-0223-x. No abstract available.

PMID:
21938496
9.

Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-β 1a treated multiple sclerosis patients.

Christophi GP, Christophi JA, Gruber RC, Mihai C, Mejico LJ, Massa PT, Jubelt B.

J Neurol Sci. 2011 Aug 15;307(1-2):41-5. doi: 10.1016/j.jns.2011.05.024. Epub 2011 Jun 11.

10.

Treatment regimens for HIV neurocognitive dysfunctions in the highly active antiretroviral therapy (HAART) era.

Jubelt B.

Curr Neurol Neurosci Rep. 2010 Nov;10(6):417-9. doi: 10.1007/s11910-010-0141-3. No abstract available.

PMID:
20717854
11.

Rapid disease course in African Americans with multiple sclerosis.

Kister I, Chamot E, Bacon JH, Niewczyk PM, De Guzman RA, Apatoff B, Coyle P, Goodman AD, Gottesman M, Granger C, Jubelt B, Krupp L, Lenihan M, Lublin F, Mihai C, Miller A, Munschauer FE 3rd, Perel AB, Teter BE, Weinstock-Guttman B, Zivadinov R, Herbert J.

Neurology. 2010 Jul 20;75(3):217-23. doi: 10.1212/WNL.0b013e3181e8e72a.

PMID:
20644149
12.

Neurologic manifestations of varicella zoster virus infections.

Amlie-Lefond C, Jubelt B.

Curr Neurol Neurosci Rep. 2009 Nov;9(6):430-4. Review.

PMID:
19818229
13.

Interferon-beta treatment in multiple sclerosis attenuates inflammatory gene expression through inducible activity of the phosphatase SHP-1.

Christophi GP, Panos M, Hudson CA, Tsikkou C, Mihai C, Mejico LJ, Jubelt B, Massa PT.

Clin Immunol. 2009 Oct;133(1):27-44. doi: 10.1016/j.clim.2009.05.019. Epub 2009 Jun 25.

14.

Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype.

Christophi GP, Panos M, Hudson CA, Christophi RL, Gruber RC, Mersich AT, Blystone SD, Jubelt B, Massa PT.

Lab Invest. 2009 Jul;89(7):742-59. doi: 10.1038/labinvest.2009.32. Epub 2009 Apr 27.

15.

Effectiveness of inactivated poliovirus vaccine.

Jubelt B.

Curr Neurol Neurosci Rep. 2008 Nov;8(6):453-4. No abstract available.

PMID:
18957180
16.

SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients.

Christophi GP, Hudson CA, Gruber RC, Christophi CP, Mihai C, Mejico LJ, Jubelt B, Massa PT.

Lab Invest. 2008 Mar;88(3):243-55. doi: 10.1038/labinvest.3700720. Epub 2008 Jan 21.

17.

Dexamethasone for adult bacterial meningitis.

Jubelt B.

Curr Neurol Neurosci Rep. 2007 Nov;7(6):459-60. No abstract available.

PMID:
17999890
18.

Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults.

Jubelt B.

Curr Neurol Neurosci Rep. 2006 Nov;6(6):451-2. No abstract available.

PMID:
17074278
19.

Post-infectious encephalomyelitis.

Mihai C, Jubelt B.

Curr Neurol Neurosci Rep. 2005 Nov;5(6):440-5. Review.

PMID:
16263054
20.

A vaccine to prevent herpes zoster and post-herpetic neuralgia in older adults.

Jubelt B.

Curr Neurol Neurosci Rep. 2005 Nov;5(6):427-8. No abstract available.

PMID:
16263052
21.

Reverse transcriptase takes ALS back to viruses.

Robberecht W, Jubelt B.

Neurology. 2005 Feb 8;64(3):410-1. No abstract available.

PMID:
15699366
22.

ALS: persistent scientists do not find persisting enteroviruses.

Jubelt B, Lipton HL.

Neurology. 2004 Apr 27;62(8):1250-1. No abstract available.

PMID:
15111658
23.

Post-Polio Syndrome.

Jubelt B.

Curr Treat Options Neurol. 2004 Mar;6(2):87-93.

PMID:
14759341
24.

Pleconaril for infantile enterovirus meningitis.

Jubelt B.

Curr Neurol Neurosci Rep. 2003 Nov;3(6):459-60. No abstract available.

PMID:
14565898
25.

Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis Consortium.

Weinstock-Guttman B, Jacobs LD, Brownscheidle CM, Baier M, Rea DF, Apatoff BR, Blitz KM, Coyle PK, Frontera AT, Goodman AD, Gottesman MH, Herbert J, Holub R, Lava NS, Lenihan M, Lusins J, Mihai C, Miller AE, Perel AB, Snyder DH, Bakshi R, Granger CV, Greenberg SJ, Jubelt B, Krupp L, Munschauer FE, Rubin D, Schwid S, Smiroldo J; New York State Multiple Sclerosis Consortium.

Mult Scler. 2003 Jun;9(3):293-8.

PMID:
12814178
26.

Valacyclovir and famciclovir therapy in herpes zoster.

Jubelt B.

Curr Neurol Neurosci Rep. 2002 Nov;2(6):477-8. No abstract available.

PMID:
12359099
27.

The neuropathology observed in wild-type mice inoculated with human poliovirus mirrors human paralytic poliomyelitis.

Ford DJ, Ropka SL, Collins GH, Jubelt B.

Microb Pathog. 2002 Sep;33(3):97-107.

PMID:
12220986
28.

Magnetic resonance imaging of mesenrhombencephalitis.

Wasenko JJ, Park BJ, Jubelt B, Lieberman KA, Swarnkar A, Joy SE, Chang JK.

Clin Imaging. 2002 Jul-Aug;26(4):237-42.

PMID:
12140152
29.
31.

Does viral disease underlie ALS? Lessons from the AIDS pandemic.

Jubelt B, Berger JR.

Neurology. 2001 Sep 25;57(6):945-6. No abstract available.

PMID:
11571314
32.

Serum insulin-like growth factor-I (IGF-I) does not correlate positively with isometric strength, fatigue, and quality of life in post-polio syndrome.

Trojan DA, Collet J, Pollak MN, Shapiro S, Jubelt B, Miller RG, Agre JC, Munsat TL, Hollander D, Tandan R, Robinson A, Finch L, Ducruet T, Cashman NR.

J Neurol Sci. 2001 Jan 1;182(2):107-15.

PMID:
11137515
33.

Characteristics and management of postpolio syndrome.

Jubelt B, Agre JC.

JAMA. 2000 Jul 26;284(4):412-4. Review. No abstract available.

PMID:
10904484
34.

A multicenter, randomized, double-blinded trial of pyridostigmine in postpolio syndrome.

Trojan DA, Collet JP, Shapiro S, Jubelt B, Miller RG, Agre JC, Munsat TL, Hollander D, Tandan R, Granger C, Robinson A, Finch L, Ducruet T, Cashman NR.

Neurology. 1999 Oct 12;53(6):1225-33.

PMID:
10522877
35.

Antibody titer to the poliovirus in blood and cerebrospinal fluid of patients with post-polio syndrome.

Jubelt B, Salazar-Grueso EF, Roos RP, Cashman NR.

Ann N Y Acad Sci. 1995 May 25;753:201-7. Review. No abstract available.

PMID:
7611629
36.

Post-polio syndrome: an update.

Jubelt B, Drucker J.

Semin Neurol. 1993 Sep;13(3):283-90. Review.

PMID:
8272600
37.

Motor neuron diseases and viruses: poliovirus, retroviruses, and lymphomas.

Jubelt B.

Curr Opin Neurol Neurosurg. 1992 Oct;5(5):655-8. Review.

PMID:
1327304
38.

Immune responses in the post-polio syndrome.

Salazar-Grueso EF, Roos RP, Jubelt B, Cashman NR.

N Engl J Med. 1992 Feb 27;326(9):641; author reply 642. No abstract available.

PMID:
1370858
39.

Peripheral nervous system involvement in multiple sclerosis.

Zee PC, Cohen BA, Walczak T, Jubelt B.

Neurology. 1991 Mar;41(3):457-60. No abstract available.

PMID:
1848689
40.

Susceptibility and resistance to poliovirus-induced paralysis of inbred mouse strains.

Jubelt B, Ropka SL, Goldfarb S, Waltenbaugh C, Oates RP.

J Virol. 1991 Feb;65(2):1035-40.

41.

Viruses and motor neuron diseases.

Jubelt B.

Adv Neurol. 1991;56:463-72. Review. No abstract available.

PMID:
1853778
42.
43.

Localization of genomic regions specific for the attenuated, mouse-adapted poliovirus type 2 strain W-2.

Pevear DC, Oh CK, Cunningham LL, Calenoff M, Jubelt B.

J Gen Virol. 1990 Jan;71 ( Pt 1):43-52.

PMID:
2154539
44.

Isoelectric focusing studies of serum and cerebrospinal fluid in patients with antecedent poliomyelitis.

Salazar-Grueso EF, Grimaldi LM, Roos RP, Variakojis R, Jubelt B, Cashman NR.

Ann Neurol. 1989 Dec;26(6):709-13.

PMID:
2513770
45.

Clearance of a persistent human enterovirus infection of the mouse central nervous system by the antiviral agent disoxaril.

Jubelt B, Wilson AK, Ropka SL, Guidinger PL, McKinlay MA.

J Infect Dis. 1989 May;159(5):866-71.

PMID:
2540248
46.

Anti-thymocyte serum delays clearance of poliovirus from the mouse central nervous system.

Jubelt B, Ropka SL, Goldfarb SJ, Janavs JL.

J Neuroimmunol. 1989 May;22(3):223-32.

PMID:
2539386
49.

Neurological manifestations of the post-polio syndrome.

Jubelt B, Cashman NR.

Crit Rev Neurobiol. 1987;3(3):199-220. Review.

PMID:
3315237
50.

Ultrastructural immunohistochemical localization of poliovirus during virulent infection of mice.

Dal Canto MC, Barbano RL, Jubelt B.

J Neuropathol Exp Neurol. 1986 Nov;45(6):613-8.

PMID:
3021913

Supplemental Content

Loading ...
Support Center